UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 107

Sortiert nach

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Journal of clinical oncology, 2019-04, Vol.37 (11), p.912-922

2019

Link zum Volltext

Verfügbarkeit prüfen

Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway

EBioMedicine, 2018-02, Vol.28 (C), p.80-89

2018

Link zum Volltext

Verfügbarkeit prüfen

Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes

PloS one, 2013-07, Vol.8 (7), p.e70428

2013

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma

British journal of haematology, 2017-08, Vol.178 (3), p.434-441

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

Blood, 2012-05, Vol.119 (22), p.5118-5125

2012

Link zum Volltext

Verfügbarkeit prüfen

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Blood, 2024-02, Vol.143 (9), p.822

2024

Link zum Volltext

Verfügbarkeit prüfen

Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy

Leukemia research, 2023-10, Vol.133, p.107374-107374, Article 107374

2023

Link zum Volltext

Verfügbarkeit prüfen

A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

Expert opinion on drug safety, 2016-09, Vol.15 (9), p.1279-1286

2016

Link zum Volltext

Verfügbarkeit prüfen

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study

Haematologica (Roma), 2019-07, Vol.104 (7), p.e293-e295

2019

Link zum Volltext

Verfügbarkeit prüfen

Poor outcomes for double‐hit lymphoma patients treated with curative‐intent second‐line immunochemotherapy following failure of intensive front‐line immunochemotherapy

British journal of haematology, 2020-04, Vol.189 (2), p.313-317

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia

Cancer, 2019-02, Vol.125 (4), p.618-625

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186

Leukemia & lymphoma, 2013-04, Vol.54 (4), p.760-766

2013

Link zum Volltext

Verfügbarkeit prüfen

Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response

American journal of hematology, 2017-10, Vol.92 (10), p.E602-E604

2017

Link zum Volltext

Verfügbarkeit prüfen

Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials

Cancer epidemiology, biomarkers & prevention, 2014-12, Vol.23 (12), p.2688-2693

2014

Link zum Volltext

Verfügbarkeit prüfen

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Blood, 2020-11, Vol.136 (Supplement 1), p.4-7

2020

Link zum Volltext

Verfügbarkeit prüfen

Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7526-7526

2022

Link zum Volltext

Verfügbarkeit prüfen

Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO)

Blood, 2020-11, Vol.136 (Supplement 1), p.21-22

2020

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Blood, 2020-11, Vol.136 (Supplement 1), p.41-42

2020

Link zum Volltext

Verfügbarkeit prüfen

Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7545-7545

2023

Link zum Volltext

Verfügbarkeit prüfen

Integration of end-of-life care in clinical trials for advanced malignancies

Journal of clinical oncology, 2017-11, Vol.35 (31_suppl), p.67-67

2017

Link zum Volltext

Verfügbarkeit prüfen

Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma (DLBCL) in clinical trials

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e19520-e19520

2013

Link zum Volltext

Verfügbarkeit prüfen

Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes

Blood, 2020-11, Vol.136 (Supplement 1), p.1-1

2020

Link zum Volltext

Verfügbarkeit prüfen

Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7510-7510

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(100)

Publikationsform

Artikel
(107)

Sprache

Englisch
(107)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(38)
Humans
(36)
Hematology
(28)
Male
(22)
Female
(21)
Aged
(20)
Middle Aged
(20)
Aged, 80 And Over
(17)
Oncology
(17)
Adult
(15)
Antineoplastic Agents - Therapeutic Use
(8)
Treatment Outcome
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)
Follow-Up Studies
(6)
Leukemia, Myeloid, Acute - Drug Therapy
(6)
Prognosis
(6)
Young Adult
(6)
Antineoplastic Agents - Adverse Effects
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway

Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy

A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study

Poor outcomes for double‐hit lymphoma patients treated with curative‐intent second‐line immunochemotherapy following failure of intensive front‐line immunochemotherapy

Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186

Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response

Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas

Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO)

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study

Integration of end-of-life care in clinical trials for advanced malignancies

Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma (DLBCL) in clinical trials

Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes

Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial

Suchergebnisse filtern